Review Article
Critical Assessment of Implantable Drug Delivery Devices in Glaucoma Management
Table 2
Examples of sustained release delivery systems for glaucoma that are under clinical development.
| Drug | Implant type | Administration route | Manufacturer | Status | Information source |
| Bimatoprost | Sustained release punctal plug | Inserted into lid puncta | Vistakon Pharmaceuticals | Completed | [36, 37] | Latanoprost | Punctal plug | Inserted into lid puncta | QLT | Completed | [38] | Latanoprost | Biodegradable DURASERT (Latanoprost) | Subconjunctival implantation | pSivida Corp. | Ongoing | [39] | Latanoprost | Nonbiodegradable pellets of Latanoprost coated with EVA | Subconjunctival implantation | Aerie Pharmaceuticals | Ongoing | [40] | Travoprost | Sustained release travoprost punctum plug | Inserted into canaliculus of the eyelid | Ocular Therapeutix | Recruiting | [41] | Ciliary neurotrophic factor | Nonbiodegradable NT 501 | Pars plana implantation | Neurotech | Ongoing | [42] | Latanoprost | Biodegradable slow release (SR) insert | Subconjunctival implantation | Sunil Deokule & Pfizer | Recruiting | [43] |
|
|